Navigation Links
Vermillion Reports Results for the Second Quarter 2011
Date:8/4/2011

nts. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty as to Vermillion's ability to protect and promote its proprietary technology; (2) Vermillion's lack of a lengthy track record successfully developing and commercializing diagnostic products; (3) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its future diagnostic products; (4) uncertainty of the size of market for its existing diagnostic tests or future diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that patients will not be able to receive reimbursement for Vermillion's tests from third party payors such as private insurance companies and government insurance plans; (5) uncertainty whether Vermillion will successfully license or otherwise successfully partner with third parties to commercialize its future products; (6) uncertainty whether the trading in Vermillion's stock will become significantly less liquid or more volatile; and (7) other factors that might be described from time to time in Vermillion's filings with the Securities and Exchange Commission. All information in this press release is as of the date of this report, and Vermillion expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Vermillion's expectations or any change in events, conditions or circumstances on which any such statement is based, unless required by law.  

This release should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent reports on Form 10-K and Form 10-Q.  Copies are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at www.sec.gov.Vermillion, Inc.Consolidated Balance Sheets(Amounts in Thousands,
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Vermillion and Stanford Scientists Receive Best Research Award From the PAD Coalition
2. Vermillion Announces Receipt of NASDAQ Panel Decision
3. Vermillion Announces Notice of Issuance of U.S. Patent Covering Hepcidin as a Biomarker for Ovarian Cancer
4. Vermillion, Inc. Files a Voluntary Petition for Reorganization Relief Under Chapter 11 of the United States Bankruptcy Code
5. Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors
6. Vermillion Announces Return of Eric Fung, M.D., Ph.D.
7. Medicare Establishes Reimbursement Coverage for Vermillions OVA1(TM) Test
8. Vermillion to Attend Society of Gynecologic Oncologists Meeting March 15-19
9. Vermillion Announces Issuance of European Patent
10. Vermillion Announces Notice of Allowance of Patent for Breast Cancer Biomarkers
11. Stephens Initiates Coverage on Vermillion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
(Date:1/14/2014)... 14, 2014 EquitiesIQ, a leading informational ... ALQA). Alliqua is an emerging biomedical company acquiring, developing, ... care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... seasoned management team and Board, which launched the company’s ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management software, today ... In this role, Michelle will work with current and potential ... development of iLab products. Her main goal will be to ... scientific community by offering the most advanced, user-friendly, and high-impact ...
(Date:1/14/2014)... 2014 Global Record Systems, LLC, ... technology solutions for patients, physicians, the biopharmaceutical industry, ... today the signing of a three-year Research Collaboration ... Administration (FDA). This initiative is designed to ...
Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... Continental Airlines CEO Larry Kellner, and the Greater Houston ... April 23 TechConnect World today announced an all-star ... TechConnect World trio of conferences -- which includes ... events, at the George R. Brown Convention Center in ...
... April 23 /PRNewswire-Asia/ -- Lotus Scarless Hair Transplantation,(International) ... their,new flagship transplant center on the prestigious Chang,an ... is the first U.S. specialized,medical and plastics institution ... With a floor area of 1,000 ...
... 22 Three attorneys who previously worked at McKenna ... Atlanta office. The attorneys include Mark S. Lange, partner, ... and Larry A. Slovensky, a partner in ... good lawyers back into the fold," said MLA chairman ...
Cached Biology Technology:TechConnect World Conference Showcases Houston Leaders May 3-7, at the George R. Brown Convention Center 2TechConnect World Conference Showcases Houston Leaders May 3-7, at the George R. Brown Convention Center 3Lotus Scarless Hair Transplantation (International) Medical Chain Institute Opens New Center on Beijing's Prestigious Chang'An Avenue 2Three Attorneys Rejoin McKenna Long & Aldridge 2
(Date:4/17/2014)... cartridge developed at Sandia National Laboratories and recently licensed ... and cheaper. , Bacillus anthracis , the ... all over the world and can cause serious, and ... bacteria can survive in harsh conditions for decades. In ... through skin contact, inhalation of spores or eating contaminated ...
(Date:4/17/2014)... cells in bone marrow need to produce hydrogen sulfide ... according to a new study from the Center for ... Dentistry of USC. , Professor Songtao Shi, principal investigator ... produced by the cells governs the flow of calcium ... signals that results in osteogenesis, or the creation of ...
(Date:4/17/2014)... parasites and pathogens that devastate honeybees in Europe, Asia ... but do not appear to be impacting native honeybee ... of researchers., The invasive pests include including Nosema ... African honeybees appear to be resilient to these invasive ... to control pests in Europe, Asia and the United ...
Breaking Biology News(10 mins):Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3
... establish a social infrastructure that facilitates successful science-based management ... networks, according to a study from the U.S. Forest ... the studywhich is featured in the January issue of ... stationcan help watershed councils increase the effectiveness of their ...
... are used to assess the intelligence of human beings. ... for bacteria ― and it may lead to new ... industry. An international team led by Prof. Eshel ... Astronomy and his research student Alexandra Sirota-Madi says that ...
... (January 21, 2011) -- The Biophysical Society,s 55th Annual ... Baltimore Convention Center in Baltimore, MD. There, more than ... in understanding and breakthroughs in technology at every level ... organisms, and environments. The Biophysical Society is the ...
Cached Biology News:Immersive data collection, peer networks among key elements of effective watershed councils 2The genius of bacteria 2Upcoming conference: Biophysical Society's 55th Annual Meeting 2
Rabbit polyclonal to Syntrophin alpha 1 ( Abpromise for all tested applications). entrezGeneID: 6640 SwissProtID: Q13424...
Mouse monoclonal [4i97] to HLA Class 1 A25 ( Abpromise for all tested applications). Antigen: Full length protein (Human): HLA Class 1 Antigen-A25. Swiss Protein ID: P18462...
Mouse Anti-Human MCAF-(MCP-1)...
LTBP-1 (E-20)...
Biology Products: